glp 1 glucagon dual receptor agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Machine learning designs new GCGR/GLP-1R
Description
It is notable that high spikes of blood insulin, (Hyperinsulinemia), initiates inflammation, which over times causes atherosclerosis and its sequela cardiovascular heart disease (CHD)
That is a meaningful gap
Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes
Conclusion From a weird gut hormone that lasted two minutes to blockbuster drugs changing how we treat diabetes, obesity, heart disease, and maybe more, the journey of GLP-1 agonists has been nothing short of remarkable
doi: 10.1056/NEJM199503093321001
